• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Our Team

o2h ventures team are leaders in the biotech community and have been actively involved as investors, holding various industry positions for over 20 years.

o2h-ventures

Sunil Shah

Managing Partner, Therapeutics

Sunil's Biography

o2h-ventures
close

Sunil Shah

Managing Partner, Therapeutics

o2h Ventures was co-founded by Sunil and Prashant Shah in 2013. In the last 3-4 years, they have co-founded four companies with UK-based academics and entrepreneurs, provided consultancy services to five companies, held Chairman or Director level positions in nine companies, built up a portfolio of twenty early-stage investments, and executed early-stage drug discovery research projects for fifteen different companies. In 2013, bucking a pattern of UK Science going to the USA for funding, Sunil and Prashant acted quickly to lead an academic spin-out from the USA with promising data in brain cancer and proceeded to run, externally fund and locate that company, Opal Oncology, in the UK. It provided direct hands-on experience of making the scientific decisions and managing the operations of a therapeutics company.

o2h-ventures

Prashant Shah

Managing Partner, AI

Prashant's Biography

o2h-ventures
close

Prashant Shah

Managing Partner, AI

o2h Ventures was co-founded by Sunil and Prashant Shah in 2013. In the last 3-4 years, they have co-founded four companies with UK-based academics and entrepreneurs, provided consultancy services to five companies, held Chairman or Director level positions in nine companies, built up a portfolio of twenty early-stage investments, and executed early-stage drug discovery research projects for fifteen different companies. In 2013, bucking a pattern of UK Science going to the USA for funding, Sunil and Prashant acted quickly to lead an academic spin out from the USA with promising data in brain cancer and proceeded to run, externally fund and locate that company, Opal Oncology, in the UK. It provided direct hands-on experience of making the scientific decisions and managing the operations of a therapeutics company.

o2h-ventures

Andy Morley

Principal

Andy's Biography

o2h-ventures
close

Andy Morley

Principal

Andy is a Medicinal Chemist with over 25 yrs working in major pharma (Sano -Aventis, AZ). He has experience across all discovery phases, having supported five candidates into the clinic. He has authored and inventor of over 55 publications and patents. He is been working full-time with o2h Ventures since 2013 to lead the scientific evaluation of the investments and also provides scientific support on key projects within the portfolio. He is the CSO of Opal Oncology and had been CSO for two o2h early-stage collaborations.

o2h-ventures

Gary Pitts

Compliance Consultant, Tetractys Limited

Gary's Biography

o2h-ventures
close

Gary Pitts

Compliance Consultant, Tetractys Limited

Gary Pitts MA(Oxon), MA(London), MBA, FInstLM, FCMI, ACSI is a senior compliance professional of 28 year's standing, a former regulator, Head of Compliance for hedge fund Brevan Howard, Head of Compliance for Europe, Mid-East, Africa and Japan for a boutique investment bank. He is a former director of regulated firms in the UK and South Africa and has been an FCA regulated person since 2001, as well as having fulfilled regulated roles in Ireland. Gary is the founder of Tetractys Partners LLP based in London, a compliance consultancy set up in 2013 which acts for asset managers, hedge funds, brokers, fintechs and consumer credit firms, as well as delivering an extensive range of public and in-house technical training courses. He is also founder and CEO of Tetractys Ireland Limited, its Irish affiliate offering similar services to the Irish market.

o2h-ventures

Catherine Beech

Independent Representative to the Investment Advisory Panel

Catherine Beech Biography

o2h-ventures
close

Catherine Beech

Independent Representative to the Investment Advisory Panel

Catherine has over 25 years of experience in biotech, pharmaceutical and as a venture investor. She is currently the CEO of Exonate for which she was one of the founders leading the spin- out from Nottingham University. Catherine has a degree in medicine from Birmingham University and in 2008 was awarded the OBE for services to technology and innovation.
o2h-ventures

Dr Chris Torrance

Independent Representative of the Investment Advisory Panel

Dr Chris Torrance Biography

o2h-ventures
close

Dr Chris Torrance

Independent Representative of the Investment Advisory Panel

Chris is a cancer researcher and entrepreneur. In 2007 he founded Horizon Discovery to translate advances in human genome editing into a range of research tools and services to accelerate the discovery of new and improved ‘Personalized Medicines’, including the identi cation of novel drug targets for pharmaceutical development. By 2014 Chris and his colleagues had built Horizon into the fastest growing Biotech company in the UK. In the same year, the company listed on the London Stock Exchange with over 100 commercial and scienti c staff and signi cant deal- ow with the pharmaceutical Industry, for which Horizon received the Queens Award for International Trade in 2012. Chris completed his post-doctoral training in the laboratory of Professor Bert Vogelstein at the Johns Hopkins University (U.S.A).
o2h-ventures

Cengiz Tarhan

Independent Representative of the Investment Advisory Panel

Cengiz Tarhan Biography

o2h-ventures
close

Cengiz Tarhan

Independent Representative of the Investment Advisory Panel

Cengiz set up FreeMedic PLC in 1993 which he grew over 25 years and is now known as UCL Business PLC, one of the most proli c and successful technology groups in the UK serving UCL and its associated partner hospitals. Over those years Cengiz was directly involved in many licenses and spinouts including PolyMASC Pharmaceuticals PLC, one of the rst university spin-outs to oat on the London AIM in 1995, Medic to Medic Ltd which was sold to Informa PLC in 2005 and Stanmore Implants Worldwide Limited which was acquired by Abingworth and MDY Healthcare in February 2008. More recently UCLB has been at the vanguard of creating the most promising cancer and gene therapy biotechs in the UK including three.
o2h-ventures

R G Boyle

Independent Representative of the Investment Advisory Panel

Robert's Biography

o2h-ventures
close

R G Boyle

Independent Representative of the Investment Advisory Panel

R G Boyle is a founder and the CEO of Sentinel Oncology Ltd, a company dedicated towards the discovery of novel small molecules for the treatment of unmet medical needs.  Robert is a medicinal chemist by background with over twenty-five years’ industrial experience.  He has held positions at Pfizer (1993-1997); Cambridge Discovery Chemistry (1997-2000); Millennium Pharmaceuticals (200-2003); Astex Therapeutics (2003-2005) & Sentinel Oncology (2005-present).  As CEO & founder of Sentinel Oncology, he has successfully raised multiple rounds of funding, built a pipeline of small molecule drug assets and secured multiple licensing deals with Biotech and Pharma.  Sentinel has been the recipient of numerous awards & grants for innovation and Robert is a named inventor on over 50 patents & publications describing the discovery and use of small molecules for the treatment of unmet medical needs.
o2h-ventures

W. Graham Richards

Independent Representative of the Investment Advisory Panel

W. Graham Richards Biography

o2h-ventures
close

W. Graham Richards

Independent Representative of the Investment Advisory Panel

Graham served as Chairman of the Department of Chemistry at Oxford University. Throughout his career, he has been involved in the commercialisation of technologies where he was a director of the University of Oxford’s technology transfer company. He was also involved with the Wellcome Trust in a similar capacity. He co-founded Oxford Molecular Group plc., InhibOx Ltd. and Oxford Drug Design Ltd. He was a main board director, now venture partner, of IP Group plc., the listed intellectual property commercialisation company.
o2h-ventures

David Barrett

Senior Venture Partner

David's Biography

o2h-ventures
close

David Barrett

Senior Venture Partner

David has spent most of his career working in Japan with Astellas and the predecessor company, Fujisawa. He is a senior-level leader and drug hunter with extensive expertise in infectious diseases and oncology, project management and has a track record of delivering quality, differentiated development candidates to the pipeline and market. In recent years, he has developed extensive management and leadership experience within Astellas with a focus on scientific excellence, effective global cross-functional interactions, leadership, responsibility, productivity, mentorship and influence. David has extensive experience working with internal and external research programs, Divisional governance, decision-making and reporting processes and interactions with domestic/overseas affiliates and partners, including CROs to help drive creation of innovative product candidates. David received his Ph.D. degree in synthetic organic chemistry from Newcastle University in the UK and carried out postdoctoral research at Stanford University in the laboratory of Professor Barry M.Trost.

o2h-ventures

Chris Reid

Venture Partner

Chris's Biography

o2h-ventures
close

Chris Reid

Venture Partner

Chris Reid worked in the City for 17 years as a successful equity research analyst and a fund manager. Amongst other achievements, he built a UK Income fund from scratch to be one of the best performing funds in the sector (150% total return in six years) with over £1bn AUM. Prior to joining the City, he spent 6 years as a Technology Consultant at PA Consultants, focusing on evaluation and support of new products and businesses. He has first-hand experience of over 200 businesses in all industries from mining to high-technology manufacturing across the UK, US and Europe and a deep understanding of the financial, strategic and operational factors that must all come together to ensure a successful, financially rewarding investment. He has a Cambridge MA in Natural Sciences (Materials Science) and an MBA from London Business School.

o2h-ventures

Dr Nigel Pitchford

Venture Partner

o2h-ventures
close

Dr Nigel Pitchford

Venture Partner

Nigel is the CEO of Ieso Digital Health Limited - the world leading digital health company specialising in evidence-based online Cognitive Behavioural Therapy (CBT). Prior to joining Ieso he was the Chief Investment Officer for Touchstone Innovations plc and was responsible for all of the Group's investment activities, which were concentrated on UK-based start-ups in the Healthcare and Technology sectors. During his tenure, the active venture portfolio grew to some 50 companies with corresponding value growth in excess of £350m. Previously he had been a partner at DFJ Esprit and 3i and was an active investor across Europe and the US. His previous investments include Domantis (sold to GSK), Arakis (sold to Sosei Pharma), Apatech (sold to Baxter), Endosense (sold to St Jude), EUSA Pharma (sold to Jazz), Horizon Discovery (AIM: HZD) and Oxford Immunotec (NASDAQ: OXFD).
o2h-ventures

Jeff Roix

Venture Partner

Jeff's Biography

o2h-ventures
close

Jeff Roix

Venture Partner

Jeff is a scientist and biotech entrepreneur with over 15 years of experience in discovering medicines. Most recently, he was founder and CEO of NeoPhore Ltd, a UK cancer immunotherapy biotech making small-molecule drugs in DNA damage repair. Prior to that, he worked as COO to establish PhoreMost, a Cambridge University spinout company making therapeutics for “undruggable” targets across many diseases. Jeff’s longer experience in translational and early drug discovery spans US organisations across venture, biotech, pharma and academic science. Jeff obtained his bachelors from the Harvard Extension School, with further training and expertise in the genetics and cell biology of cancer, diabetes and metabolic disease.

o2h-ventures

Riddhi Ahuja

Senior Fund Operations Manager

Riddhi's Biography

o2h-ventures
close

Riddhi Ahuja

Senior Fund Operations Manager

Riddhi is the Senior Fund Operations Manager at o2h ventures and also the EA to CEO. She acts as a liaison for fund-related matters and looks out for deal flow that comes in from prospective investee companies. She has extensive experience as an operations and international business manager in a reputed manufacturing firm. Riddhi has expertise in the field of business administration, marketing, finance and international business management. She has a bachelor’s degree in Business Administration from ICFAI university..

o2h-ventures

Priyanka Patel

Head of Finance

Priyanka's Biography

o2h-ventures
close

Priyanka Patel

Head of Finance

Priyanka is the head of Finance for o2h Ventures. She is responsible for managing finance and accounting, internal audit and financial due diligence of portfolio companies. Moreover, she ensures all the statutory FCA compliances and protection of client money. She is a chartered accountant with over 6 years of experience in the finance and accounting industry. 

o2h-ventures

Ajit Singh Guller

Marketing Manager

Ajit's Biography

o2h-ventures
close

Ajit Singh Guller

Marketing Manager

As o2h Group’s Marketing Manager, Ajit leads a team of bright marketing professionals focused on strengthening the o2h group brand in the industry and spotting business growth opportunities. Ajit is responsible for brand marketing, advertising and research, content and digital marketing, business analytics, PR and communications. Prior to joining o2h Group, Ajit worked as a digital marketer for two SME tech companies with global client bases and a seed stage ecommerce startup. He is an experienced professional with an eye for design, user experience and behaviour, and digital analytics.

o2h-ventures

Juhi Shah

Marketing Manager - o2h Ventures

Juhi's biography

o2h-ventures
close

Juhi Shah

Marketing Manager - o2h Ventures

Juhi is the Marketing Manager at o2h Ventures, overseeing the entire marketing lifecycle. She is responsible for curating various marketing content which includes blogs, social media, and websites to generate organic as well as paid traffic and contribute to the company’s revenue. She has previous experience working in the financial and accounting sectors prior to joining o2h Ventures. She has a master's degree in business administration from PDEU University.

Speak to a member of our team
Contact Us
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • o2h Ventures deals pipeline, Knowledge-intensive EIS Fund closing on 5th April 2023
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)